Not every day you see an anti-obesity drug that has an average of >24% body weight loss
🆕 @NEJM#ADA2023 nejm.org/doi/full/10.10…
Triple receptor agonist weight loss exceeds prior GLP-1 drugs (and dual receptor agents) and has yet to plateau pic.twitter.com/djCzivBA5E
Teacher, Clinical Supervisor
Clinical Associate Professor, Psychiatry
University of Florida
Affiliation is for identification only. All content and opinions are my own.
View more posts
Gator Psychiatry 